In this perspective, we present our assessment of all of the known accumulated evidence on the role of neoadjuvant therapy in the management of borderline resectable pancreatic cancer highlighting the gaps in the data, the current regimens used and providing a brief insight into the way forward.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133292 | PMC |
http://dx.doi.org/10.1007/s13193-021-01361-1 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!